State Street’s Artiva Biotherapeutics ARTV Stock Holding History

State Street’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$231K	Hold	35,824	–	–	﹤0.01%	3852
2025 Q4	$154K	Sell	35,824 -24,000	-40%	-$90.6K	﹤0.01%	3961
2025 Q3	$172K	Sell	59,824 -3,050	-5%	-$8.16K	﹤0.01%	3950
2025 Q2	$94.9K	Sell	62,874 -108,909	-63%	-$229K	﹤0.01%	3986
2025 Q1	$515K	Buy	171,783 +7,000	+4%	+$37.8K	﹤0.01%	3582
2024 Q4	$1.66M	Buy	164,783 +78,224	+90%	+$940K	﹤0.01%	3375
2024 Q3	$1.34M	Buy	+86,559	New	+$1M	﹤0.01%	3429

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

Revelation Capital Management Sausalito, California $67.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

State Street's ARTV Position: Q1 2026 in Review

State Street held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 35,824 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #3852.

State Street first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.66M in Q4 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

State Street held 35,824 shares of Artiva Biotherapeutics worth $231K as of Q1 2026.
State Street left its Artiva Biotherapeutics share count unchanged in Q1 2026.
Artiva Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3852 holding.
State Street first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
State Street's Artiva Biotherapeutics position peaked at $1.66M in Q4 2024.
40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.